Zhuang Jingru, Ren Ying, Chen Minmin, Yue Minghui, Yuan Changyong, Duan Rongquan
School of Stomatology, Xuzhou Medical University, Xuzhou, Jiangsu 221004, China.
The Affiliated Stomatological Hospital of Xuzhou Medical University, Xuzhou, Jiangsu 221002, China.
iScience. 2025 Mar 7;28(4):112182. doi: 10.1016/j.isci.2025.112182. eCollection 2025 Apr 18.
Our meta-analysis aimed to evaluate the efficacy of localized sustained-release drugs in periodontitis and comorbid diabetes. PubMed, Cochrane Library, Embase, and Web of Science were comprehensively searched until 4 December 2024, and 10 randomized controlled trials (RCTs) were included. The results indicated that, compared to the control group, localized sustained-release drugs significantly reduced probing depth (PD) (SMD = -0.77, 95% confidence interval [CI] (-1.37, -0.16)) but did not reduce clinical attachment loss (CAL) (SMD = -0.18, 95% CI (-0.60, 0.23)), sites with glycated hemoglobin (HbA1c) (SMD = 0.03, 95% CI (-0.38, 0.43)), plaque index (SMD = -0.37, 95% CI (-0.80, 0.06)), sites with bleeding on probing (BOP) (SMD = -0.26, 95% CI (-0.68, 0.16)), and gingival index (SMD = 0.07, 95% CI (-0.30, 0.44)). Subgroup analysis by different drugs elicited that, compared to the control treatment, chlorhexidine was effective in reducing BOP% (SMD = -0.55, 95% CI (-0.90, -0.19)). Our meta-analysis finds that the efficacy of localized sustained-release drugs in periodontitis and comorbid diabetes is limited.
我们的荟萃分析旨在评估局部缓释药物在牙周炎合并糖尿病中的疗效。全面检索了PubMed、Cochrane图书馆、Embase和科学网，直至2024年12月4日，纳入了10项随机对照试验（RCT）。结果表明，与对照组相比，局部缓释药物显著降低了探诊深度（PD）（标准化均数差[SMD]=-0.77，95%置信区间CI），但未降低临床附着丧失（CAL）（SMD=-0.18，95%CI(-0.60,0.23)）、糖化血红蛋白（HbA1c）水平（SMD=0.03，95%CI(-0.38,0.43)）、菌斑指数（SMD=-0.37，95%CI(-0.80,0.06)）、探诊出血（BOP）部位（SMD=-0.26，95%CI(-0.68,0.16)）和牙龈指数（SMD=0.07，95%CI(-0.30,0.44)）。不同药物的亚组分析表明，与对照治疗相比，氯己定在降低BOP%方面有效（SMD=-0.55，95%CI(-0.90,-0.19)）。我们的荟萃分析发现，局部缓释药物在牙周炎合并糖尿病中的疗效有限。
